J Parkinsons Dis 7:289299 Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G (1996) Reduced intravenous glutathione in the treatment of early Parkinson's disease
Most patients tolerate GLP-1 medications well, and with appropriate management strategies, side effects can usually be minimised whilst maintaining the significant metabolic benefits these medications provide
We take your medical history, assess the area, and talk through realistic expectations
This protocol offers a high degree of flexibility with incubation times (20-30 minutes for sample incubation and conjugate incubation, 10-15 minutes for TMB substrate incubation) allowing for simple, efficient, and flexible automation programming on open pipetting systems
It might be the dose, the titration speed, a concurrent medication, an underlying condition, or a shift to a different GLP-1 medication entirely (tirzepatide, for instance, shows stronger average weight loss in head-to-head comparisons)